



Doramapimod

Cat. No.:	OB0225LY-0428
Appearance:	Solid
Purity:	≥98%
Identity:	Confirmed by NMR, HPLC, and LC-MS.
Size:	5 mg; 10 mg; 25 mg; 50 mg; 100 mg; 200 mg; 500 mg; 1 g


This product is for research use only and is not intended for diagnostic use.

Product Overview

Description	Doramapimod is a small molecule MAPK pathway inhibitor that primarily targets p38 MAPK.
Synonym	BIRB 796; 285983-48-4; BIRB-796; BIRB 796 (Doramapimod); BIRB796; BIRB-796 BS; BIRB 796 BS; 3-[3- <i>tert</i> -Butyl-1-(4-methylphenyl)-1 <i>H</i> -pyrazol-5-yl]-1-[4-[2-(morpholin-4-yl)ethoxy]naphthalen-1-yl]urea; 1-[5- <i>tert</i> -Butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea; 1-(3-(<i>tert</i> -Butyl)-1-(<i>p</i> -tolyl)-1 <i>H</i> -pyrazol-5-yl)-3-(4-(2-morpholinoethoxy)naphthalen-1-yl)urea
CAS No.	285983-48-4
Compound CID	156422
Formula	C ₃₁ H ₃₇ N ₅ O ₃
Formula Weight	527.66

Specification

Relative Density	1.2 g/cm ³
IUPAC Name	1-[5- <i>tert</i> -Butyl-2-(4-methylphenyl)pyrazol-3-yl]-3-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]urea
InChI	InChI=1S/C31H37N5O3/c1-22-9-11-23(12-10-22)36-29(21-28(34-36)31(2,3)4)33-30(37)32-26-13-14-27(25-8-6-5-7-24(25)26)39-20-17-35-15-18-38-19-16-35/h5-14,21H,15-20H 2,1-4H3,(H2,32,33,37)
InChI Key	MVCOAUNKQVWQH-Z-UHFFFAOYSA-N



SMILES string	<chem>CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5</chem>
Stability	3 years in powder form.
Storage	Storage at -20°C.
Applications	Doramapimod can be used in cell signaling studies to explore the role of p38 MAP K in different biological processes.

Library Information

Targets	Serine/Threonine kinases
Receptors	p38 MAPK; p38α; Raf
Pathways	MAPK; Autophagy
Plate Number	AOCL-6
Plate Location	e4
Empty Location	a1-h1; a12-h12
Container	96-well plate
Formulation	10 mM DMSO
DMSO Max Solubility	20 mg/mL; 37.9 mM
Ethanol Max Solubility	26.4 mg/mL; 50 mM
AlogP	5.907
HBA_Count	4
HBD_Count	2
Rotatable Bond	8